Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 10/20 | 0.55 |
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | HPN | P05981 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7898123 | 0.81 | PIK3CD (0.66) | SLC16A3MAOBMAOANPC1MEN1 | |
| SCHEMBL4951498 | 0.78 | GLA (0.62) | MAOBNPC1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL16826561 | 0.77 | GLA (0.60) | MAOBNPC1MEN1KMT2AKDM4E | |
| SCHEMBL7898144 | 0.77 | KDM4E (0.62) | SLC16A3MAOBMAOANPC1MEN1 | |
| SCHEMBL93260 | 0.73 | SLC16A3 (1.00) | SLC16A3MAOBMAOANPC1MEN1 | |
| SCHEMBL4648135 | 0.73 | SLC16A3 (0.66) | SLC16A3MAOBMAOANPC1MEN1 | |
| SCHEMBL29066609 | 0.73 | SLC16A3 (0.70) | SLC16A3MAOBMAOANPC1MEN1 | |
| SCHEMBL7910817 | 0.73 | SLC16A3 (0.56) | SLC16A3MAOBMAOANPC1MEN1 | |
| SCHEMBL1093778 | 0.72 | MAOB (0.72) | SLC16A3MAOBMAOANPC1MEN1 | |
| SCHEMBL104995 | 0.72 | AR (0.67) | SLC16A3MAOBMAOANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9182402-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140127127-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-05-08 | — | — | US | disclosed |
| US-8664266-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130289105-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER CENTER | 2013-10-31 | — | — | US | disclosed |
| US-8450334-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110144139-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127127-A1 | HEPSIN INHIBITORS | HPN, TMPRSS2, SPINT2 | SLC16A3 3108/4885MAOB 2847/4885MAOA 3521/4885 |
| US-20110144139-A1 | HEPSIN INHIBITORS | HPN, TMPRSS2, SPINT2 | SLC16A3 3108/4885MAOB 2847/4885MAOA 3521/4885 |
| US-20130289105-A1 | HEPSIN INHIBITORS | HPN, TMPRSS2, SPINT2 | SLC16A3 3108/4885MAOB 2847/4885MAOA 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.